Immunomodulating Agents as Antipruritics

Dermatol Clin. 2018 Jul;36(3):325-334. doi: 10.1016/j.det.2018.02.014. Epub 2018 Apr 16.

Abstract

Chronic pruritus, or itch lasting greater than 6 weeks, is an increasingly common and debilitating medical problem. Recent studies have unveiled previously unrecognized neuroimmune axes whereby inflammatory cytokines act directly on the nervous system to promote itch. Thus, the emergence of newer targeted biologic therapies has generated the possibility of novel treatment strategies for chronic itch disorders. This article reviews the pathophysiology of multiple chronic itch disorders, including atopic dermatitis, chronic idiopathic pruritus, chronic urticaria, and prurigo nodularis. Furthermore, new and emerging immunomodulatory therapies that will likely alter current treatment paradigms are discussed.

Keywords: Atopic dermatitis; Chronic idiopathic pruritus; Immunomodulator; Itch; Prurigo nodularis; Pruritus; Urticaria.

Publication types

  • Review

MeSH terms

  • Antipruritics / administration & dosage
  • Antipruritics / therapeutic use*
  • Biological Products / therapeutic use*
  • Dermatitis / complications
  • Dermatitis / drug therapy
  • Dermatitis / immunology*
  • Histamine Antagonists / therapeutic use
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Interleukins / antagonists & inhibitors*
  • Janus Kinase Inhibitors / therapeutic use
  • Omalizumab / therapeutic use
  • Prurigo / drug therapy
  • Pruritus / drug therapy*
  • Pruritus / etiology
  • Urticaria / drug therapy*

Substances

  • Antipruritics
  • Biological Products
  • Histamine Antagonists
  • Immunologic Factors
  • Interleukins
  • Janus Kinase Inhibitors
  • Omalizumab